Complement 3 Glomerulopathy (C3G) Epidemiology Forecast

Complement 3 Glomerulopathy (C3G) Insights and Trends

• C3G presents with various glomerulonephritis patterns, including membrano-proliferative, mesangial proliferative, diffuse endo-capillary proliferative, and crescentic types.
• Two forms of C3G have been found through several secondary sources, namely Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN), which vary as per the patterns of damage and inflammation in the glomeruli. In addition, it is important to note that the features of DDD tend to appear earlier than those of C3GN, usually in adolescence.
• C3G is associated with a challenging long-term outlook, driven by its progressive course and high risk of recurrence. Approximately 30–50% of patients develop End-stage Kidney Disease (ESKD) within 10 years of diagnosis.
• The diagnosed prevalent population of C3G in the 7MM is expected to grow between 2025 and 2036, driven by advancements in complement biology and enhanced diagnostic capabilities. Greater use of genetic testing, complement assays, and renal biopsy interpretation supported by multidisciplinary collaboration is enabling earlier and more accurate diagnosis.
• The total diagnosed prevalent cases of C3G in the US were around 3,500 in 2025. These cases are expected to rise at a CAGR of 2.2%. This growth is driven by multiple factors, including enhanced diagnostic capabilities, increased disease awareness, broader inclusion of both acquired and genetic forms in reporting, and expanded population screening.
• In 2025, C3G predominantly affected adults in Germany, with ~500 cases, while the paediatric population accounted for ~30 cases. By 2036, these numbers are expected to rise in adults and in children.

Complement 3 Glomerulopathy (C3G) Epidemiology Forecast in the 7MM

• 2025 Projected C3G Diagnosed Prevalent Cases: ~3,500
• C3G Growth Rate (2026–2036): 1.9% CAGR

DelveInsight's ‘Complement 3 Glomerulopathy (C3G) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the C3G, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Complement 3 Glomerulopathy (C3G) Understanding and Diagnosis Algorithm

Complement 3 Glomerulopathy (C3G) Overview and Diagnosis

Complement 3 glomerulopathy (C3G), a term established by expert consensus in 2013, refers to a group of rare kidney diseases caused by dysregulation of the alternative complement pathway. It is characterized by predominant C3 deposition in the glomeruli with minimal or absent immunoglobulin, C1q, and C4, making this the key diagnostic feature in patients presenting with glomerulonephritis. Clinically, C3G presents with proteinuria, hematuria, reduced urine output, low blood protein levels, and edema. Due to its rarity, epidemiological estimates remain uncertain. Diagnosis typically requires a kidney biopsy with evaluation through light microscopy, immunofluorescence (showing dominant C3 staining), and electron microscopy, which further classifies the disease into dense deposit disease (DDD) or C3 glomerulonephritis (C3GN); additional assessments include urine and blood tests and glomerular filtration rate (GFR) measurement.

Complement 3 Glomerulopathy (C3G) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent population of C3G, type-specific diagnosed prevalent population of C3G, age-specific diagnosed prevalent population of C3G, and total treated cases of C3G in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan from 2022 to 2036.

• In 2025, the diagnosed prevalent population of C3G in the 7MM was around 6,000. This number is expected to rise through 2036, driven by advances in complement biology, improved diagnostics, and wider use of genetic testing, complement assays, and multidisciplinary biopsy evaluation.
• The diagnosed prevalent population of C3G in the US was around 3,500 in 2025.
• In 2025, C3G predominantly affected adults in the US, with 90% of the cases, while the paediatric population accounted for the remaining 10%.
• In Japan, adults are more prevalent in C3G compared to paediatrics.
• C3GN is the most common form of C3G, accounting for the majority of cases. It accounted for approximately 80% cases in the 7MM.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of C3G, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• C3G Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-Year Forecast
• Patient Burden Trends (By Geography)

FAQs

• What are the disease risks, burdens, and unmet needs of C3G? What will be the growth opportunities across the 7MM concerning the patient population with C3G?
• What is the historical and forecasted C3G patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.